Quotient (QTNT) Stock Price, News & Analysis

Company Overview

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.19 to $0.80
• 52-Week Range: N/A
• Volume: 5.81 million shs
• Average Volume: 437,886 shs
• Market Capitalization: $980 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

QTNT Stock Analysis - Frequently Asked Questions

How were Quotient's earnings last quarter?

Quotient Limited (NASDAQ:QTNT) released its quarterly earnings results on Thursday, August, 5th. The company reported ($9.60) EPS for the quarter, beating analysts' consensus estimates of ($10.40) by $0.80. The business earned $9.09 million during the quarter, compared to analysts' expectations of $9.10 million.

When did Quotient's stock split?

Quotient shares reverse split on Thursday, November 3rd 2022.The 1-40 reverse split was announced on Thursday, November 3rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 3rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Quotient own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quotient investors own include Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F), Wayfair (W), Zomedica (ZOM), Wells Fargo & Company (WFC) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/05/2021
• Today: 10/18/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:QTNT
• CIK: 1596946
• Web: www.quotientbd.com
• Phone: (122) 716-9800
• Fax: N/A
• Employees: 426
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($53.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$125.13 million
• Net Margins: -413.55%
• Pretax Margin: -411.03%
• Return on Equity: N/A
• Return on Assets: -88.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.79
• Quick Ratio: 1.36

Sales & Book Value

• Annual Sales: $38.51 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($56.17) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,580,000
• Free Float: 2,309,000
• Market Cap: $980 thousand
• Optionable: Optionable
• Beta: 2.32